← Home / Aquestive Therapeutics, Inc. (AQST)
Stock Analysis
Aquestive Therapeutics, Inc. (AQST)
AQST
AQST · Market data
3.69 -0.67%
Track AQST in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when AQST price is:
52W Range Position
16%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 16:45 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Strong / Strong
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
4.07
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
13
●
Financial Results
HIGH
Aquestive Therapeutics Reports First Quarter 2026 Financial Results
(NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic business update.
8-K Filing • SEC EDGAR
What's Driving AQST?
📈 Technical recovery is improving
Momentum is Neutral. Watch 4.07 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
38.9
Price Chart
AQST — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$459.2M
Company size
EV
$393.6M
Debt-adjusted value
P/E
-6.7
Not meaningful
P/S
9.1
Balanced
P/B
-13.5
Not meaningful
EV/Sales
7.8
Balanced
EV/EBIT
-7.0
Not meaningful
P/FCF
-10.4
Not meaningful
FCF Yield
-9.65%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Improving business, cash flow needs monitoring
Growth, profitability, cash flow and balance sheet quality remain broadly supportive.
↗
Revenue Growth
Strong
●
Profitability
Strong
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
14.45M
↗ Strong
📈 Net Income
-8.06M
↗ Strong
🧮 EPS (Basic)
-0.07
↗ Strong
Aquestive Therapeutics, Inc.
Related Opportunities